Hyperdilute CaHA is the clearest example in injectable aesthetics of a single device doing two unrelated clinical jobs depending on how you prepared it. Same syringe, same particles, same box. Injected neat, it is a structural volumiser. Injected at 1:2 or beyond, it contributes almost no volume at all and behaves as a diffuse collagen stimulator across a field.
That is not a marketing distinction and it is not a matter of injector preference. It is a physical consequence of what dilution does to a particulate suspension, and if you write "CaHA" in a treatment plan without a ratio next to it, you have not specified the treatment.
This page is the mechanism, the ratios, the planes, and — because this changed in 2026 and most injectors have not caught up — the current regulatory position.
What is actually in the syringe
Calcium hydroxylapatite for aesthetic use is a suspension, not a gel.
Per the FDA labelling, it is a sterile, non-pyrogenic, semi-solid, cohesive implant whose principal component is synthetic calcium hydroxylapatite suspended in a gel carrier of sterile water for injection, glycerin and sodium carboxymethylcellulose, with a CaHA particle size range of 25 to 45 microns. The composition is commonly described in the peer-reviewed literature as approximately 30% smooth CaHA microspheres in a 70% aqueous sodium carboxymethylcellulose carrier.
Two components, two timelines. The carrier gel occupies space immediately and then resorbs over weeks. The microspheres persist, fibroblasts adhere to them, and neocollagenesis and elastogenesis proceed around them. Light microscopy at six months post-injection shows microspheres stable at the dermal–subcutaneous junction, surrounded by thick collagen and fibroelastic tissue, without granuloma formation, migration or significant inflammation. Type I collagen predominates by six months and the effect has been observed to persist for up to 18 months.
Neat, the product is highly viscoelastic and gives an immediate, near one-to-one correction — 1 mL of product yields roughly 1 mL of volume correction (Durairaj KK, Yambao M, Linnemann-Heath J, Dhiman A. Aesthet Surg J Open Forum. 2025;7:ojaf104. doi:10.1093/asjof/ojaf104).
What dilution physically does
Add saline and/or lidocaine and four things happen at once.
Particle concentration per millilitre falls. You still have the same number of microspheres in the syringe, but they are now distributed through three or four times the injected volume.
Viscoelasticity falls. The preparation stops behaving like a cohesive implant and starts behaving like something that flows. That is what makes superficial and subdermal placement feasible at all — neat product in a superficial plane is a visible ridge.
Spread increases dramatically. The same syringe now covers a field rather than filling a defect. This is the point.
The immediate volumising effect falls disproportionately. Not linearly — it drops away, because the carrier that was doing the space-occupying is now mostly added diluent that will be absorbed within a day or two.
So you have traded correction for coverage. You are no longer treating a defect; you are treating a region.
Why spreading the particles might do more, not less
The working model is a spacing argument. Wider dispersion puts more microspheres in contact with more fibroblasts across a larger area, which is hypothesised to stimulate a more uniform and more widespread biostimulatory response than the same number of particles concentrated in a bolus. Because that interaction depends on the spacing of the microspheres, the degree of dilution becomes a determinant of the biostimulatory result rather than just a determinant of spread.
Be precise about the epistemic status here: that is a well-supported hypothesis about mechanism, not a measured dose-response curve. There is no published study establishing an optimal microsphere spacing or demonstrating that 1:3 produces more collagen per particle than 1:1. What is documented is the clinical direction — diluted and hyperdiluted preparations placed subdermally enhance skin tightening while minimising volumising effects.
Mechanistic work is starting to fill in the biology. A 2026 report in the International Journal of Dermatology describes CaHA injection improving senile purpura through YAP-mediated mechanotransduction — fibroblasts responding to the mechanical environment the particles create (Seo J, Kim H, Goo BL, Park JY, Rho NK, Lee S. Int J Dermatol. 2026;65:1553–1556. doi:10.1111/ijd.70320). Mechanotransduction is a plausible bridge between "particles are spaced through the tissue" and "fibroblasts make collagen", but it is early.
The ratio table
| Preparation | Goal | Typical region | Plane | Immediate volume |
|---|---|---|---|---|
| Neat | Structural contour and projection | Chin, jawline, temples | Supraperiosteal / deep subdermal | Yes, ~1:1 |
| 1:1 | Moderate volume with smoother transitions | Midface, transitions between compartments | Subdermal | Partial |
| 1:2 | Skin quality and firmness, face | Cheeks, perioral, décolleté | Subdermal | Negligible |
| 1:3 | Diffuse tightening across a field | Neck, décolleté, body, mid and lower face | Subdermal, multilayered | None intended |
| 1:4 | Diffuse tightening in thin skin | Thin-skinned regions and patients | Subdermal / superficial subdermal | None |
Maritza Mejia teaches the working distinction as: diluted is 1:1; hyperdiluted is anything above 1:1, up to 3:1 or 4:1. The goal at the hyperdilute end is to diffuse — to work on skin tightening and skin quality rather than to add volume — and the explicit technical instruction is to avoid delivering big boluses, because a bolus of a preparation you diluted specifically so it would spread is how you get a palpable ball where you wanted a field effect.
The published ratio conventions line up with that. A 1:1 dilution is commonly used for moderate volume enhancement with smoother tissue transitions; 1:2 is often preferred for facial applications where negligible immediate volumisation and pronounced biostimulation are wanted; 1:3 is typical for the neck, décolletage and body; and 1:4 is generally recommended for thinner skin.
The regulatory position changed in 2026
This is the part most injectors are still getting wrong, and it is worth updating your consent language.
Mixing with lidocaine has been on-label since 2009. The FDA approved detailed instructions for mixing CaHA with 2% lidocaine hydrochloride, producing a final concentration of 0.3% lidocaine, for the approved indication of subdermal implantation for correction of moderate to severe facial wrinkles and folds (PMA P050052/S019, approved 13 July 2009). A pre-mixed lidocaine formulation followed in 2015.
Dilution with saline became partly on-label on 31 March 2026. The FDA approved an expanded indication for CaHA diluted 1:2 with 0.9% sterile saline solution, for subdermal implantation for the correction of décolleté wrinkles in patients 22 years of age and older (PMA P050052/S162).
The approval carries a specified preparation, and it is worth knowing because it is now the only fully specified diluted protocol in US labelling:
- 1.5 mL of product to 3.0 mL of 0.9% sterile saline.
- Injected subdermally with a 22 G, 50 mm flexible cannula.
- Into a defined central décolleté region of approximately 100 cm², bounded superiorly by the sternoclavicular notch, laterally by the midclavicular lines, and inferiorly by the superior point of the intermammary cleft, with no injection over breast tissue.
- Three treatments, at day 1, week 6 and week 12.
The pivotal trial randomised 152 patients 3:1 to treatment or untreated control. At week 24, the responder rate on the Merz Aesthetic Scale for décolleté wrinkles at rest was 71.2% in the treatment group against 6.3% in the untreated control, assessed live by blinded evaluators. Treatment-emergent adverse events attributed to treatment occurred in 11.7% of treated patients, all mild to moderate.
Everything else remains off-label. Facial hyperdilution at any ratio, body hyperdilution, neck, hands, 1:3 and 1:4 preparations — all off-label use. That is permissible within your scope and is ordinary practice in this specialty, but it should be named as such in your consent and your notes, and it is a different conversation from the one you have about the décolleté protocol.
The rest of the on-label indications for reference: subdermal implantation for correction of moderate to severe facial wrinkles and folds such as nasolabial folds; restoration or correction of the signs of facial fat loss in people with HIV; hand augmentation to correct volume loss in the dorsum of the hands (2015); and, for the lidocaine-containing formulation, deep subdermal and/or supraperiosteal injection for soft tissue augmentation to improve moderate to severe loss of jawline contour in adults over 21 (2021).
Preparing it
The mechanics matter more than they look.
Use a Luer-lock connector and two syringes. The kit used in the pivotal décolleté trial consisted of two 5 mL Luer-lock syringes, a Luer-lock connector, an 18 G blunt needle and 0.9% sterile saline. Transfer back and forth until the suspension is homogeneous. A partially mixed preparation deposits unevenly, which is the whole failure mode you diluted to avoid.
Decide diluent before you decide ratio. Saline dilutes. Lidocaine dilutes and anaesthetises but adds a drug with its own dose ceiling, which matters when you are treating a large field and may be combining with other anaesthesia. If you are treating a 100 cm² décolleté or a full neck, do the lidocaine arithmetic rather than assuming.
Mix immediately before injection. Do not prepare and leave standing.
Record the ratio in the notes. Product, ratio, diluent, total injected volume, plane and region. Six weeks later, "she had Radiesse" tells you nothing about what to do next.
Technique consequences
Dilution changes the injection, not just the preparation.
The delivery is fanning, not depositing. Retrograde threads, multiple passes, deliberate overlap. A cannula is the usual choice at hyperdilute ratios because you are covering area and want fewer entry points.
The plane is subdermal, and it should be consistent. Multilayered techniques exist and are published, but inconsistent plane control at a single intended depth is the more common problem. Uneven depth produces uneven response, and uneven response is what you will be looking at in five months.
Avoid boluses absolutely. The label's general instruction not to over-correct applies with more force here, because the preparation is not meant to correct anything focally.
It is not reversible. There is no hyaluronidase equivalent for CaHA. Unlike hyaluronic acid, where a bad result has an exit, a hyperdilute CaHA result is a result you live with while it resorbs. Empire's page on dissolving filler is about HA and does not apply here — a distinction worth making explicitly to patients who assume all fillers are reversible.
Remember it is radiopaque. CaHA particles are clearly visible on CT and may be visible on plain radiography. Patients should be told, so they can inform other clinicians and radiologists.
The label does not support use in the lips. Safety and effectiveness for lip use has not been established and nodules following lip injection are reported in the labelling.
What the diffuse approach is good for
The clinical niche is specific: a field deficit rather than a focal one.
Crepey texture over a thin, depleted dermis. A neck or décolleté where any volumising product would be actively wrong. Dorsal hands. Perioral rhytids, where a pilot study of 1:3 hyperdilute CaHA to the perioral region — two sessions at weeks 1 and 8 — was followed by hyaluronic acid at week 16, treating quality and structure as separate jobs in sequence (Somenek M. Aesthet Surg J Open Forum. 2024;6:ojae021. doi:10.1093/asjof/ojae021).
And the mid and lower face, where the objective data is now reasonably good. A retrospective chart review of 22 patients treated with 1:3 hyperdilute CaHA in two sessions at day 0 and day 30 found, at day 150 on 3D imaging, significant improvement in cheek volume and significant reductions in jowl volume, nasolabial fold depth and marionette line depth (Durairaj et al., 2025). Note the shape of that result: jowl volume down, nasolabial fold depth down. That is not a volumising result. That is what a diffuse biostimulator looks like when it works.
These dilution ratios and technique specifics reflect Maritza Mejia's clinical practice as taught in Empire Medical Training's hands-on curriculum. Technique is learned under supervision; this article is educational and is not a substitute for training. Dilution and hyperdilution outside the approved 1:2 décolleté indication is off-label use requiring your own clinical judgement and documented consent. Verify against current labelling before treating.
Where this is trained
Mixing, cannula control at a consistent subdermal plane, and knowing when a field has had enough are hands-on skills, and the failure modes of hyperdilution are tactile ones. Empire's Facial Contouring Injectables workshop covering Sculptra, Radiesse, exosomes and PDRN covers the preparation and placement directly, and the Neck and Hands Rejuvenation Master Course addresses the regions where hyperdilution does most of its work. Anatomical Based Aesthetics Training is the anatomy foundation underneath both.
Related guides in this cluster
Part of Treatment Planning and Layering.
Clinical GuideThe Collagen Stimulator Landscape: Skin Boosters vs Biostimulators vs Fillers, ComparedSkin boosters vs biostimulators vs fillers, compared by goal, plane, onset and failure mode — a four-category clinical matrix for injec
Clinical GuideChoose by Tissue Diagnosis, Not by Trend: A Collagen Biostimulator Decision TreeA collagen biostimulator decision tree for injectors — four tissue findings, four products, and the five-point compass behind every sel
Clinical GuideThe Biostimulator Results Timeline: Why Three Months, and How to Set It at ConsultationThe biostimulator results timeline injectors should set at consultation: why day-zero fullness is water, when collagen shows, and the s
Train with Empire
This guide is clinical education. The technique behind it is taught hands-on, on live patients, with faculty beside you.
Explore Anatomical-Based Aesthetics Training →Disclaimer
This article reflects the clinical opinions and experience of Maritza Mejia, FNP, an independent faculty member contributing to Empire Medical Training's curriculum. The views expressed are the author's own and do not necessarily represent those of Empire Medical Training.
It is professional education, not medical advice, and is no substitute for hands-on training or independent clinical judgment. Licensed clinicians remain responsible for their own patient selection, technique and outcomes, for verifying current product labelling, and for practising within their scope and applicable law. Empire Medical Training accepts no liability for reliance on this content.